Technological Innovation and Social Commitment
ADmit Therapeutics S.L. is a pioneering company in the application of innovative technologies in the field of neurodegenerative diseases, with a strong social component. Its main asset is a highly trained team with experience in medical diagnostics, neurobiology, artificial intelligence, and the development and marketing of medical devices. Its quality is demonstrated by the clearance of the manufacturing license from the Spanish Agency of Medicines and Medical Devices (AEMPS), the ISO 13485 certification, and the laboratory accreditation from the College of American Pathologists (CAP), becoming the first Spanish laboratory to achieve this recognition.
In addition to the development and commercialization of the MAP-AD® test, the company continues to work to incorporate new solutions in the field of neurodegenerative diseases to improve the quality of life of patients and their families.
Innovation
Our team has an innovative vision that has allowed us to develop a disruptive approach to the market.
Efficiency and Effectiveness
We optimize our resources to achieve each of our scientific and business objectives.
Agility
We adopt agile and solid decisions to achieve our goals within the agreed timeframe.
A crucial step towards personalized medicine
The MAP-AD® test provides a prognosis for the progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia. This solution links disease biology, mitochondrial dysfunction, with cognitive changes. This is achieved through the analysis of novel blood biomarkers, mitochondrial DNA methylation, along with key disease risk factors (ApoE genotype and age), and neuropsychological assessment. Predicting cognitive decline years in advance opens the door to earlier interventions and optimizes patient selection for clinical trials, representing a significant advance in personalized and precision medicine.
Lastest news
- November 14, 2024
ADmit Therapeutics receives accreditation from the College of American Pathologists
Barcelona – November 14, 2024. The Committee on Accreditation of the College of American Pathologists (CAP) has granted accreditation to ADmit Therapeutics, Barcelona, based on the results of the recent on-site inspection conducted as part of CAP’s Accreditation Programmes. The director of the laboratory, Dr. Marta Blanch was notified of this national recognition and congratulated […]
- June 15, 2024
ADmit Therapeutics extends the scope of its ISO13485
ADmit Therapeutics announces that it has successfully passed the annual external audit, demonstrating that the medical device quality management system and its effectiveness are adequately maintained. We are pleased to share that, in our tireless effort to pursue excellence in quality, the scope of our ISO13485:2016 certification has been expanded to include the manufacturing of […]
- May 21, 2024
ADmit Therapeutics has been selected to join StartUp Health’s Alzheimer’s Moonshot Community.
21 of May, 2024 ADmit Therapeutics, has been selected to be part of the prestigious Alzheimer’s Moonshot Community driven by StartUp Health. This initiative brings together startups, investors and organisations focused on accelerating transformative solutions for the prevention, detection and treatment of Alzheimer’s disease. Through this inclusion, ADmit Therapeutics will have access to a global […]
Team
Members of the Board of Directors
Ferran
Prat
Chairman of the Board of Directors
Marta Barrachina
Co-Founder
CEO
Santiago Lozano
Board of
Directors
Maite
Fibla
Board of
Directors
This project has received funding from the European Union’s H2020 research and innovation program under number 960327.
